Medtronic (NYSE:MDT) said today that it’s starting a large study on the effect of pulse oximetry and capnography in opioid-induced respiratory depression, using its Capnostream device. The 1,650-patient Prodigy study aims to create a tool to score the risk of OIRD in patients being treated with opioids for pain, using Capnostream’s continuous pulse oximetry and capnography monitoring […]
Covidien closes $300 million Oridion deal
MassDevice.com +3 | The top 3 med-tech stories for April 5, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Oridion shares spike 70% on Covidien merger news
Federal Circuit reverses course, reinstates Marine Polymer’s $29M win over Hemcon | Legal News
A sharply split federal appeals court reversed course and reinstated a $29.4 million win for Marine Polymer Technologies in its wound dressing patent spat with HemCon Medical Technologies.
The U.S. Court of Appeals for the Federal Circuit, in an en banc decision joined in full by 5 of 9 judges on the panel, ruled that the "intervening rights" of a company accused of patent infringement are only valid when patent claim language is changed during re-examination.
Elekta’s Q3 sales spike, earnings soar | Earnings Roundup
Thoratec settles Oracle beef | Wall Street Beat
Thoratec Corp. (NSDQ:THOR) said it reached an agreement with one of its major institutional shareholders, Oracle Investment Management, over whether or not the heart pump maker should hire an investment bank to find a buyer.
Greenwich, Conn.-based Oracle, which holds a 5.2% stake in the heart pump maker, recommended that Thoratec retain an investment bank to explore strategic alternatives, including sale to a larger company.
Oridion can resume importing most of its medical devices into the U.S.
Oridion Systems Ltd. (PINK:ORDNF) can resume importing medical devices into the U.S., after the FDA reduced its ban on the company to include just 2 of its product lines.
On Dec. 20, 2011, the Israeli med-tech maker was barred by the FDA from importing any medical devices into the U.S, after the agency said the company failed to fix violations at its Jerusalem manufacturing facility.
MassDevice.com +7 | Synthes goes after Stryker, Oridion shares drop after import ban, FDA aims at reused med-tech, Accuray and Siemens amend ties, SNN spins out biologics unit, FDA releases December recalls and St. Jude expands in Plymouth
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MassDevice.com +3 | U-Wisc. chair under fire for MDT ties, Texas medical supplier gets 12 years, FDA bans Oridion-shares fall 40%
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3. And Happy New Year from the MassDevice team!
FDA bans Oridion imports, share prices dive 40%
The FDA banned Oridion Systems Ltd. (PINK:ORDNF) from importing any medical devices into the U.S., after the Israeli med-tech maker failed to fix violations at its Jerusalem manufacturing facility.
Shares of Oridion fell 39% on news of the ban, from $11.00 to $6.65 at market opening Dec. 27.
